JP2020516590A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020516590A5 JP2020516590A5 JP2019553212A JP2019553212A JP2020516590A5 JP 2020516590 A5 JP2020516590 A5 JP 2020516590A5 JP 2019553212 A JP2019553212 A JP 2019553212A JP 2019553212 A JP2019553212 A JP 2019553212A JP 2020516590 A5 JP2020516590 A5 JP 2020516590A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- individual
- oncolytic virus
- virus
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022136745A JP7597384B2 (ja) | 2017-04-14 | 2022-08-30 | 膀胱癌の治療方法 |
| JP2024006788A JP2024028541A (ja) | 2017-04-14 | 2024-01-19 | 膀胱癌の治療方法 |
| JP2026000350A JP2026042875A (ja) | 2017-04-14 | 2026-01-05 | 膀胱癌の治療方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762485805P | 2017-04-14 | 2017-04-14 | |
| US62/485,805 | 2017-04-14 | ||
| US201762500729P | 2017-05-03 | 2017-05-03 | |
| US62/500,729 | 2017-05-03 | ||
| PCT/US2018/027549 WO2018191654A1 (en) | 2017-04-14 | 2018-04-13 | Methods of treating bladder cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022136745A Division JP7597384B2 (ja) | 2017-04-14 | 2022-08-30 | 膀胱癌の治療方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020516590A JP2020516590A (ja) | 2020-06-11 |
| JP2020516590A5 true JP2020516590A5 (https=) | 2021-06-17 |
Family
ID=63792825
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019553212A Pending JP2020516590A (ja) | 2017-04-14 | 2018-04-13 | 膀胱癌の治療方法 |
| JP2022136745A Active JP7597384B2 (ja) | 2017-04-14 | 2022-08-30 | 膀胱癌の治療方法 |
| JP2024006788A Pending JP2024028541A (ja) | 2017-04-14 | 2024-01-19 | 膀胱癌の治療方法 |
| JP2026000350A Pending JP2026042875A (ja) | 2017-04-14 | 2026-01-05 | 膀胱癌の治療方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022136745A Active JP7597384B2 (ja) | 2017-04-14 | 2022-08-30 | 膀胱癌の治療方法 |
| JP2024006788A Pending JP2024028541A (ja) | 2017-04-14 | 2024-01-19 | 膀胱癌の治療方法 |
| JP2026000350A Pending JP2026042875A (ja) | 2017-04-14 | 2026-01-05 | 膀胱癌の治療方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (4) | US11338003B2 (https=) |
| EP (2) | EP4599893A3 (https=) |
| JP (4) | JP2020516590A (https=) |
| KR (1) | KR102949236B1 (https=) |
| CN (1) | CN110573624A (https=) |
| AU (1) | AU2018251987B2 (https=) |
| ES (1) | ES3030923T3 (https=) |
| PL (1) | PL3610026T3 (https=) |
| WO (1) | WO2018191654A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3426271T3 (pl) | 2016-03-10 | 2025-11-24 | Cg Oncology, Inc. | Sposoby leczenia guzów litych terapią skojarzoną |
| AU2018251987B2 (en) | 2017-04-14 | 2024-11-28 | Cg Oncology, Inc. | Methods of treating bladder cancer |
| EP3708657A4 (en) * | 2017-11-08 | 2021-08-25 | Kagoshima University | ONCOLYTIC VIRUS (ONCOLYTIC IMMUNOTHERAPY) THAT IS CAPABLE OF TREATING METASTATIC CANCER ALSO WITH ENSURED SAFETY, WITH EXPRESSION CONTROL SYSTEM THAT BUILDS AN OPTIMAL EXPRESSION LEVEL |
| WO2020014543A2 (en) | 2018-07-11 | 2020-01-16 | Actym Therapeutics, Inc. | Engineered immunostimulatory bacterial strains and uses thereof |
| US20200222477A1 (en) * | 2019-01-10 | 2020-07-16 | Trizell Ltd. | Method to Curtail the Progression of Non-Muscle Invasive Bladder Cancer To Muscle-Invasive Cancer |
| US12024709B2 (en) | 2019-02-27 | 2024-07-02 | Actym Therapeutics, Inc. | Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment |
| CN113748124A (zh) | 2019-02-27 | 2021-12-03 | 阿克蒂姆治疗有限公司 | 工程化以定植肿瘤、肿瘤驻留免疫细胞和肿瘤微环境的免疫刺激性细菌 |
| CA3161450A1 (en) | 2019-11-12 | 2021-05-20 | Actym Therapeutics, Inc. | Immunostimulatory bacteria delivery platforms and their use for delivery of therapeutic products |
| WO2022036159A2 (en) | 2020-08-12 | 2022-02-17 | Actym Therapeutics, Inc. | Immunostimulatory bacteria-based vaccines, therapeutics, and rna delivery platforms |
| CA3235418A1 (en) | 2021-11-09 | 2023-05-19 | Actym Therapeutics, Inc. | Immunostimulatory bacteria for converting macrophages into a phenotype amenable to treatment, and companion diagnostic for identifying subjects for treatment |
| WO2025251009A1 (en) * | 2024-05-31 | 2025-12-04 | Cg Oncology, Inc. | Methods of treating bladder cancer using an oncolytic virus and a transduction-enhancing agent |
| WO2025251014A1 (en) * | 2024-05-31 | 2025-12-04 | Cg Oncology, Inc. | Methods and compositions for biomarker-guided bladder cancer therapy |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4590071A (en) | 1984-09-25 | 1986-05-20 | Xoma Corporation | Human melanoma specific immunotoxins |
| US7001764B2 (en) | 1995-06-27 | 2006-02-21 | Cell Genesys, Inc. | Compositions comprising tissue specific adenoviral vectors |
| US6051227A (en) | 1995-07-25 | 2000-04-18 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| JP2002514074A (ja) | 1997-03-03 | 2002-05-14 | セル ジェネシス，インコーポレイティド | 異種転写調節エレメントを含有するアデノウイルスベクターおよびその使用方法 |
| US6432700B1 (en) | 1997-03-03 | 2002-08-13 | Cell Genesys, Inc. | Adenovirus vectors containing heterologous transcription regulatory elements and methods of using same |
| US6900049B2 (en) | 1998-09-10 | 2005-05-31 | Cell Genesys, Inc. | Adenovirus vectors containing cell status-specific response elements and methods of use thereof |
| AU2003252891B2 (en) | 1998-09-10 | 2006-06-01 | Cold Genesys, Inc. | Adenovirus vectors containing cell status-specific response elements and methods of use thereof |
| US6682736B1 (en) | 1998-12-23 | 2004-01-27 | Abgenix, Inc. | Human monoclonal antibodies to CTLA-4 |
| US7109003B2 (en) | 1998-12-23 | 2006-09-19 | Abgenix, Inc. | Methods for expressing and recovering human monoclonal antibodies to CTLA-4 |
| US6495130B1 (en) | 1998-12-30 | 2002-12-17 | Calydon, Inc. | Target cell-specific adenoviral vectors containing E3 and methods of use thereof |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| IL148079A0 (en) | 1999-08-24 | 2002-09-12 | Medarex Inc | Human ctla-4 antibodies and compositions containing the same |
| US7048920B2 (en) | 2000-03-24 | 2006-05-23 | Cell Genesys, Inc. | Recombinant oncolytic adenovirus for human melanoma |
| AU2001247648B2 (en) | 2000-03-24 | 2006-03-30 | Cold Genesys, Inc. | Cell-specific adenovirus vectors comprising an internal ribosome entry site |
| US6692736B2 (en) | 2000-03-24 | 2004-02-17 | Cell Genesys, Inc. | Cell-specific adenovirus vectors comprising an internal ribosome entry site |
| JP2004501631A (ja) | 2000-06-28 | 2004-01-22 | ジェネティックス・インスチチュート・リミテッド・ライアビリティ・カンパニー | Ｐｄ−ｌ２分子：新規ｐｄ−１リガンドおよびその使用 |
| BR0309254A (pt) | 2002-04-12 | 2005-03-01 | Medarex Inc | Uso de um anticorpo anti-ctla-4 |
| CN1753912B (zh) | 2002-12-23 | 2011-11-02 | 惠氏公司 | 抗pd-1抗体及其用途 |
| US7459154B2 (en) | 2002-12-26 | 2008-12-02 | Cell Genesys, Inc. | Methods and reagents for the enhancement of virus transduction in the bladder epithelium |
| AU2003299971A1 (en) | 2002-12-30 | 2004-07-29 | Amgen Inc. | Combination therapy with co-stimulatory factors |
| US20040197312A1 (en) | 2003-04-02 | 2004-10-07 | Marina Moskalenko | Cytokine-expressing cellular vaccine combinations |
| US20050282280A1 (en) | 2003-08-28 | 2005-12-22 | Ennist David L | Oncolytic adenoviral vectors encoding GM-CSF |
| WO2005030261A1 (en) | 2003-08-28 | 2005-04-07 | Cell Genesys, Inc. | Oncolytic adenoviral vectors encoding gm-csf |
| US20050186178A1 (en) | 2003-08-28 | 2005-08-25 | Ennist David L. | Oncolytic adenoviral vectors encoding GM-CSF |
| US7473418B2 (en) | 2004-03-25 | 2009-01-06 | Cell Genesys, Inc. | Pan cancer oncolytic vectors and methods of use thereof |
| TW200607859A (en) | 2004-08-23 | 2006-03-01 | Cell Genesys Inc | Oncolytic adenoviral vectors encoding GM-CSF |
| US20060062764A1 (en) | 2004-08-25 | 2006-03-23 | Seshidar-Reddy Police | Fiber-modified adenoviral vectors for enhanced transduction of tumor cells |
| DK2650020T3 (en) | 2005-05-06 | 2017-01-16 | Providence Health & Services - Oregon | Trimeric OX40 immunoglobulin fusion protein and methods for applications. |
| GB0522476D0 (en) | 2005-11-03 | 2005-12-14 | Biovex Ltd | Oncolytic herpes virus vectors |
| US8557257B2 (en) | 2006-03-24 | 2013-10-15 | Oncovac Inc. | Mycobacterial immunotherapy for cancer treatment |
| JP6092497B2 (ja) | 2006-03-30 | 2017-03-08 | ユニバーシティー オブ カリフォルニア | 抗ｃｔｌａ−４抗体の限局性分泌のための方法および組成物 |
| US7919079B2 (en) | 2006-03-31 | 2011-04-05 | Biosante Pharmaceuticals, Inc. | Cancer immunotherapy compositions and methods of use |
| CN103536915A (zh) | 2006-12-27 | 2014-01-29 | 埃默里大学 | 用于治疗传染病和肿瘤的组合物和方法 |
| US8840881B2 (en) | 2008-08-28 | 2014-09-23 | Aduro Gvax Inc. | Methods and compositions for treating prostate cancer or inducing a humoral immune response against prostate cancer |
| HRP20170165T1 (hr) | 2008-12-22 | 2017-04-07 | Targovax Oy | Onkolitički adenovirusni vektori i metode i uporabe u vezi s time |
| US9345787B2 (en) | 2008-12-22 | 2016-05-24 | Targovax Oy | Adenoviral vectors and methods and uses related thereto |
| BR112012000536A2 (pt) | 2009-07-08 | 2020-08-11 | Kymab Limited | métodos para produção de anticorpo ou cadeia leve ou pesada de anticorpo específico para um antígeno desejado, para produção de anticorpo ou cadeia de anticorpo e seu uso, composição farmacêutica e derivado de anticorpo quimérico |
| KR20130108371A (ko) | 2010-09-24 | 2013-10-02 | 온코스 테라퓨틱스 오와이 | 단클론 항―ｃｔｌａ－４ 항체를 암호화하는 종양분해 아데노바이러스 벡터 |
| US9056133B2 (en) | 2011-05-25 | 2015-06-16 | Cti-S.A. | Pharmaceutical kit and method for treating cancer |
| DK2806883T3 (da) | 2012-01-25 | 2019-07-22 | Dnatrix Inc | Biomarkører og kombinationsterapier under anvendelse af onkolytisk virus og immunomodulation |
| AR090263A1 (es) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
| CA2877414A1 (en) | 2012-07-30 | 2014-02-06 | Alex Wah Hin Yeung | Live and in-vivo tumor specified cancer vaccine system |
| ES3011466T3 (en) | 2013-04-18 | 2025-04-07 | Tilt Biotherapeutics Oy | Enhanced adoptive cell therapy |
| CA2931322A1 (en) | 2013-11-22 | 2015-05-28 | Dnatrix, Inc. | Adenovirus expressing immune cell stimulatory receptor agonist(s) |
| AU2015289081B2 (en) | 2014-07-16 | 2020-02-06 | Transgene Sa | Combination of oncolytic virus with immune checkpoint modulators |
| TWI716362B (zh) | 2014-10-14 | 2021-01-21 | 瑞士商諾華公司 | 針對ｐｄ－ｌ１之抗體分子及其用途 |
| US10583198B2 (en) * | 2015-03-12 | 2020-03-10 | Viventia Bio Inc. | Dosing strategies for targeting EPCAM positive bladder cancer |
| JP6954648B2 (ja) * | 2015-10-19 | 2021-10-27 | シージー オンコロジー， インコーポレイテッド | 併用療法による固形腫瘍又はリンパ系腫瘍の治療方法 |
| PL3426271T3 (pl) | 2016-03-10 | 2025-11-24 | Cg Oncology, Inc. | Sposoby leczenia guzów litych terapią skojarzoną |
| AU2018251987B2 (en) | 2017-04-14 | 2024-11-28 | Cg Oncology, Inc. | Methods of treating bladder cancer |
-
2018
- 2018-04-13 AU AU2018251987A patent/AU2018251987B2/en active Active
- 2018-04-13 EP EP25171388.9A patent/EP4599893A3/en active Pending
- 2018-04-13 US US16/605,066 patent/US11338003B2/en active Active
- 2018-04-13 KR KR1020197033495A patent/KR102949236B1/ko active Active
- 2018-04-13 JP JP2019553212A patent/JP2020516590A/ja active Pending
- 2018-04-13 EP EP18784592.0A patent/EP3610026B1/en active Active
- 2018-04-13 PL PL18784592.0T patent/PL3610026T3/pl unknown
- 2018-04-13 CN CN201880025068.1A patent/CN110573624A/zh active Pending
- 2018-04-13 ES ES18784592T patent/ES3030923T3/es active Active
- 2018-04-13 WO PCT/US2018/027549 patent/WO2018191654A1/en not_active Ceased
-
2022
- 2022-04-05 US US17/713,975 patent/US12370229B2/en active Active
- 2022-06-16 US US17/842,406 patent/US11596660B2/en active Active
- 2022-08-30 JP JP2022136745A patent/JP7597384B2/ja active Active
-
2024
- 2024-01-19 JP JP2024006788A patent/JP2024028541A/ja active Pending
-
2025
- 2025-06-10 US US19/233,891 patent/US20260014218A1/en active Pending
-
2026
- 2026-01-05 JP JP2026000350A patent/JP2026042875A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020516590A5 (https=) | ||
| JP2019507761A5 (https=) | ||
| CN110741081B (zh) | 肿瘤选择性tata盒和caat盒突变体 | |
| US20130345295A1 (en) | Targeted oncolytic adenovirus for treatment of human tumors, constrcution method and application thereof | |
| Yuan et al. | Mesenchymal stem cells deliver and release conditionally replicative adenovirus depending on hepatic differentiation to eliminate hepatocellular carcinoma cells specifically | |
| JP7144915B2 (ja) | 腫瘍を治療するためのウイルス | |
| JP2020533411A5 (https=) | ||
| CN102796709A (zh) | 肝癌特异性基因-病毒及其应用 | |
| JP7336791B2 (ja) | 腫瘍を治療するためのコクサッキーウイルスｂ群 | |
| EP4717766A1 (en) | Dendritic cell-targeted viroid dvlp, and preparation method therefor and use thereof | |
| CN109568350B (zh) | 一种用于治疗肿瘤的柯萨奇病毒 | |
| WO2019091457A1 (zh) | 肝脏特异性转录调控序列及其应用 | |
| WO2020233102A1 (zh) | 一种治疗肿瘤或癌症的药物组合物和其应用 | |
| US20240189374A1 (en) | Adenovirus for treatment of cancer | |
| US11951141B2 (en) | Replication-enhanced oncolytic adenoviruses | |
| CN101643750B (zh) | 靶向性溶肿瘤腺病毒载体Ad-TD-gene的构建方法及应用 | |
| CN115747174B (zh) | 重组溶瘤病毒rVSVM51R-C在乙肝性肝癌中的应用 | |
| CN108685905A (zh) | 维生素c在增强溶瘤腺病毒杀伤肿瘤细胞能力中的应用 | |
| Garcia-Aragoncillo et al. | Design of virotherapy for effective tumor treatment | |
| CN115948411A (zh) | 竞争性表达的il-12和il-23及其基因、重组载体和在制备治疗肿瘤药物中的应用 | |
| CA3070628C (en) | Enterovirus d68 (ev-d68) for treatment of tumor | |
| CN115806944A (zh) | 重组溶瘤病毒rVSVM51R-S在乙肝性肝癌中的应用 | |
| CN116179602A (zh) | 一种sinv感染性载体及其在制备抗肿瘤药物中的应用 | |
| CN116590242A (zh) | 一种重组溶瘤腺病毒及其应用 | |
| WO2004078987A1 (en) | A recombinant constructed by a virus vector and a human tumor suppressor gene and its use |